UY35258A - ANTICUERPOS ANTI-PDGFR-beta Y USOS DE LOS MISMOS - Google Patents

ANTICUERPOS ANTI-PDGFR-beta Y USOS DE LOS MISMOS

Info

Publication number
UY35258A
UY35258A UY0001035258A UY35258A UY35258A UY 35258 A UY35258 A UY 35258A UY 0001035258 A UY0001035258 A UY 0001035258A UY 35258 A UY35258 A UY 35258A UY 35258 A UY35258 A UY 35258A
Authority
UY
Uruguay
Prior art keywords
pdgfr
antibodies
beta
diseases
same
Prior art date
Application number
UY0001035258A
Other languages
English (en)
Spanish (es)
Inventor
Stanley J Wiegand
Ivan B Lobov
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of UY35258A publication Critical patent/UY35258A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
UY0001035258A 2013-01-09 2014-01-07 ANTICUERPOS ANTI-PDGFR-beta Y USOS DE LOS MISMOS UY35258A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750437P 2013-01-09 2013-01-09
US201361863452P 2013-08-08 2013-08-08
US201361909421P 2013-11-27 2013-11-27

Publications (1)

Publication Number Publication Date
UY35258A true UY35258A (es) 2014-08-29

Family

ID=50002880

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035258A UY35258A (es) 2013-01-09 2014-01-07 ANTICUERPOS ANTI-PDGFR-beta Y USOS DE LOS MISMOS

Country Status (21)

Country Link
US (3) US9265827B2 (OSRAM)
EP (1) EP2943218B1 (OSRAM)
JP (1) JP6367233B2 (OSRAM)
KR (1) KR102146692B1 (OSRAM)
CN (1) CN104936614B (OSRAM)
AU (3) AU2014205641B2 (OSRAM)
BR (1) BR112015016312B1 (OSRAM)
CA (1) CA2897383C (OSRAM)
CL (2) CL2015001924A1 (OSRAM)
EA (2) EA031049B1 (OSRAM)
IL (2) IL239552B (OSRAM)
JO (1) JO3405B1 (OSRAM)
MX (1) MX363635B (OSRAM)
MY (1) MY169165A (OSRAM)
NZ (1) NZ709683A (OSRAM)
PH (1) PH12015501493A1 (OSRAM)
SG (2) SG10201701308VA (OSRAM)
TW (1) TWI647239B (OSRAM)
UY (1) UY35258A (OSRAM)
WO (1) WO2014109999A1 (OSRAM)
ZA (1) ZA201504537B (OSRAM)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
EP3019243A4 (en) 2013-07-12 2017-03-15 Ophthotech Corporation Methods for treating or preventing ophthalmological conditions
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
ES2800674T3 (es) 2014-03-21 2021-01-04 X Body Inc Polipéptidos biespecíficos de unión a antígeno
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP2017534644A (ja) 2014-11-10 2017-11-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ａｎｇ２抗体及び使用方法
CN107074942A (zh) 2014-11-10 2017-08-18 豪夫迈·罗氏有限公司 抗‑IL‑1β抗体和使用方法
CN107148429B (zh) * 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗体及び眼科に使用する方法
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
EP3253413A2 (en) * 2015-02-06 2017-12-13 Kadmon Corporation, LLC Immunomodulatory agents
EP3973977A1 (en) 2015-03-31 2022-03-30 Ildong Pharm Co., Ltd. Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
EP3792279A3 (en) 2015-07-29 2021-07-07 Allergan, Inc. Heavy chain only antibodies to ang-2
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
ES2981791T3 (es) 2015-12-16 2024-10-10 Regeneron Pharma Composiciones y métodos para fabricar micropartículas de proteína
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
CA3029332A1 (en) * 2016-07-01 2018-01-04 Ludwig Institute For Cancer Research Ltd Methods and compositions for pdgf-cc inhibition
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN109021104B (zh) * 2017-06-12 2022-08-12 上海睿智化学研究有限公司 一种抗人血小板衍生生长因子β受体的抗体及其应用
AU2018298039B2 (en) 2017-07-06 2023-02-02 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
SG11202004380QA (en) 2017-12-22 2020-06-29 Regeneron Pharma System and method for characterizing drug product impurities
CN111655722A (zh) 2018-01-31 2020-09-11 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
BR112020013426A2 (pt) 2018-02-28 2020-12-01 Regeneron Pharmaceuticals, Inc. métodos para identificação de um vírus em uma amostra e para detecção de ácidos nucleicos virais em uma amostra de cultura de células
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
EA202092203A1 (ru) 2018-03-19 2020-12-07 Ридженерон Фармасьютикалз, Инк. Способы анализа и реагенты для микрочипового капиллярного электрофореза
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
GB201806918D0 (en) * 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
CN108586611B (zh) * 2018-04-28 2021-01-26 暨南大学 重组全人源抗破伤风毒素单克隆抗体
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
EA202092684A1 (ru) 2018-08-27 2021-03-11 Ридженерон Фармасьютикалз, Инк. Применение рамановской спектроскопии для последующей очистки
TWI866924B (zh) 2018-08-30 2024-12-21 美商再生元醫藥公司 用於將蛋白質複合物定特徵之方法
EP3868781A4 (en) * 2018-10-05 2022-07-06 Seoul National University R & DB Foundation PDGF RECEPTOR ANTIBODIES AND ITS USE
CN117110492A (zh) 2019-01-16 2023-11-24 瑞泽恩制药公司 鉴别蛋白质中的游离巯基的方法
ES2984072T3 (es) * 2019-03-08 2024-10-28 Linxis B V Moléculas de unión internalizantes que actúan sobre receptores implicados en la proliferación celular o en ladiferenciación celular
KR20220050087A (ko) 2019-05-03 2022-04-22 싱가포르 헬스 서비시즈 피티이 엘티디 대사성 질환의 치료 및 예방
SG11202110911RA (en) 2019-05-13 2021-10-28 Regeneron Pharma Improved competitive ligand binding assays
BR112022004885A2 (pt) 2019-09-24 2022-06-07 Regeneron Pharma Sistemas e métodos para uso e regeneração de cromatografia
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
IL293112A (en) 2019-11-25 2022-07-01 Regeneron Pharma Sustained release formulations using non-aqueous emulsions
WO2021142086A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
BR112022014212B1 (pt) 2020-01-21 2024-01-23 Regeneron Pharmaceuticals, Inc Métodos de análise de uma amostra incluindo uma proteína de interesse
CN115335403A (zh) * 2020-02-07 2022-11-11 毕欧丽安技术有限公司 血小板衍生生长因子受体（pdgfr）抗体、其缀合物、组合物及用途
KR20230058094A (ko) 2020-08-31 2023-05-02 리제너론 파아마슈티컬스, 인크. 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략
EP4214235A1 (en) * 2020-09-16 2023-07-26 LinXis B.V. Internalizing binding molecules
WO2022115588A1 (en) 2020-11-25 2022-06-02 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
US12350374B2 (en) 2020-12-17 2025-07-08 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
JP2024503408A (ja) 2021-01-20 2024-01-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 細胞培養におけるタンパク質力価の改善方法
JP2024512299A (ja) 2021-03-03 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質の粘度を定量及び変更するためのシステム及び方法
US20220309215A1 (en) 2021-03-26 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
CA3220848A1 (en) 2021-06-01 2022-12-08 Timothy Riehlman Microchip capillary electrophoresis assays and reagents
US20230077710A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
CN118139881A (zh) 2021-09-20 2024-06-04 瑞泽恩制药公司 控制抗体异质性的方法
IL311248A (en) 2021-10-07 2024-05-01 Regeneron Pharma PH meter calibration and repair
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
TW202330104A (zh) 2021-10-26 2023-08-01 美商再生元醫藥公司 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
EP4493921A1 (en) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
EP4634659A1 (en) 2022-12-16 2025-10-22 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2024158880A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
EP4655595A1 (en) 2023-01-25 2025-12-03 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
AU2024265540A1 (en) 2023-05-01 2025-10-30 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
TW202528736A (zh) 2023-09-08 2025-07-16 美商再生元醫藥公司 用於評估層析管柱完整性的方法及系統
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
TW202532098A (zh) 2023-09-29 2025-08-16 美商再生元醫藥公司 使用控制成核之冷凍乾燥
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
TW202535934A (zh) 2023-11-02 2025-09-16 美商再生元醫藥公司 利用應力來降低脂酶活性的方法
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
CN118440214B (zh) * 2024-04-02 2025-01-28 山东大学 一种靶向PDGFRβ的嵌合抗原受体、CAR-T细胞及应用
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU1411092A (en) 1991-01-31 1992-09-07 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
NZ246242A (en) * 1991-12-02 1996-01-26 Cor Therapeutics Inc Inhibiting immunoglobulins acting on beta-platelet derived growth factor (pdgf)
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5620687A (en) 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP2281885A1 (en) 2003-08-27 2011-02-09 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
MX2009011226A (es) * 2007-04-17 2010-04-01 Imclone Llc Inhibidores especificos pdgfrbeta.
EA200901646A1 (ru) 2007-06-05 2010-08-30 Йел Юниверсити Ингибиторы рецепторных тирозинкиназ и их применение
EP2190836B1 (en) 2007-08-22 2011-08-17 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
SI2274008T1 (sl) 2008-03-27 2014-08-29 Zymogenetics, Inc. Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
EP3028707A1 (en) 2009-05-01 2016-06-08 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
BR112013017752A8 (pt) 2011-01-13 2018-01-09 Regeneron Pharma uso de um antagonista do vegf e formulação farmacêutica
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CN102250249A (zh) 2011-06-18 2011-11-23 常州亚当生物技术有限公司 一种抗VEGF/PDGFRbeta双特异性抗体及其应用

Also Published As

Publication number Publication date
EA031049B1 (ru) 2018-11-30
AU2018202814A1 (en) 2018-05-10
US20170210813A1 (en) 2017-07-27
AU2014205641B2 (en) 2017-08-24
NZ709683A (en) 2019-01-25
MY169165A (en) 2019-02-20
US9265827B2 (en) 2016-02-23
AU2018202814B9 (en) 2019-06-06
CA2897383A1 (en) 2014-07-17
ZA201504537B (en) 2016-07-27
US20160122433A1 (en) 2016-05-05
BR112015016312B1 (pt) 2020-12-15
IL239552B (en) 2019-01-31
SG11201505035YA (en) 2015-07-30
IL245040A0 (en) 2016-05-31
EP2943218B1 (en) 2018-08-08
JP2016504416A (ja) 2016-02-12
IL245040B (en) 2020-05-31
KR20150103682A (ko) 2015-09-11
EA201890143A2 (ru) 2018-05-31
CL2015001924A1 (es) 2016-06-10
WO2014109999A1 (en) 2014-07-17
TWI647239B (zh) 2019-01-11
AU2017245479B2 (en) 2018-01-25
PH12015501493B1 (en) 2015-09-28
AU2017245479C1 (en) 2018-08-16
EP2943218A1 (en) 2015-11-18
HK1214969A1 (en) 2016-08-12
JP6367233B2 (ja) 2018-08-01
KR102146692B1 (ko) 2020-08-21
EA201890143A3 (ru) 2018-09-28
CL2018000703A1 (es) 2018-07-06
CA2897383C (en) 2021-07-06
AU2017245479A1 (en) 2017-11-02
SG10201701308VA (en) 2017-03-30
EA201591072A1 (ru) 2015-12-30
CN104936614A (zh) 2015-09-23
JO3405B1 (ar) 2019-10-20
US10023642B2 (en) 2018-07-17
US20140193402A1 (en) 2014-07-10
AU2014205641A1 (en) 2015-07-23
AU2018202814B2 (en) 2019-04-18
PH12015501493A1 (en) 2015-09-28
MX2015008689A (es) 2015-10-05
IL239552A0 (en) 2015-08-31
TW201441261A (zh) 2014-11-01
CN104936614B (zh) 2018-09-18
MX363635B (es) 2019-03-29
US9650444B2 (en) 2017-05-16

Similar Documents

Publication Publication Date Title
UY35258A (es) ANTICUERPOS ANTI-PDGFR-beta Y USOS DE LOS MISMOS
CO2017002719A2 (es) Anticuerpos anti-glucagón
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
MX2015010599A (es) Anticuerpos dirigidos contra il-33 y sus usos.
ECSP19020740A (es) Anticuerpos anti-cd27
CR20160501A (es) Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa
MX373280B (es) Anticuerpos anti-egfrviii y usos de los mismos.
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
UY35399A (es) Conjugados de fármacos con anticuerpos
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
AR092188A1 (es) ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO
CO2020004075A2 (es) Anticuerpos monoclonales anti-trkb y métodos de uso
MX2019002166A (es) Agonistas del receptor cxcr3.
CO7400866A2 (es) Anticuerpos anti-receptor de procineticinas (prokr) y usos de los mismos
AR094379A1 (es) ANTICUERPOS ANTI-PDGFR-b Y SUS USOS
AR111715A1 (es) ANTICUERPOS ANTI-SIRPa
AR129996A2 (es) Anticuerpos dirigidos contra il-33 y sus usos
AR115423A2 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
AR096092A1 (es) ANTICUERPOS ANTI-IGF-1R CON ABOLICIÓN DE LA UNIÓN AL FcRn Y SU UTILIZACIÓN EN EL TRATAMIENTO DE ENFERMEDADES OCULARES VASCULARES
AR097099A1 (es) Anticuerpos anti-activina a y usos de los mismos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211028